Research ArticleArticle
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre-Sancho, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay and Ricardo Blanco on behalf of the Tofacitinib PsA Clinical Practice Collaborative Group
The Journal of Rheumatology April 2021, jrheum.201204; DOI: https://doi.org/10.3899/jrheum.201204
Eva Galíndez-Agirregoikoa
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Diana Prieto-Peña
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
José Luis Martín-Varillas
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Beatriz Joven
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Olga Rusinovich
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Rafael B. Melero-González
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Francisco Ortiz-Sanjuan
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Raquel Almodóvar
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Juan José Alegre-Sancho
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Ángels Martínez
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Agustí Sellas-Fernández
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Lara Méndez
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Rosario García-Vicuña
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Belén Atienza-Mateo
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Iñigo Gorostiza
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Miguel Ángel González-Gay
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
Ricardo Blanco
E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. Email: rblanco@humv.es, miguelaggay@hotmail.com. Accepted for publication March 12, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre-Sancho, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay, Ricardo Blanco
The Journal of Rheumatology Apr 2021, jrheum.201204; DOI: 10.3899/jrheum.201204
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre-Sancho, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay, Ricardo Blanco
The Journal of Rheumatology Apr 2021, jrheum.201204; DOI: 10.3899/jrheum.201204